Overview

Adjuvant Chemotherapy In Elderly With Colon Cancer Stage III

Status:
Active, not recruiting
Trial end date:
2032-01-01
Target enrollment:
Participant gender:
Summary
This is a phase 2, randomized study where the aim of the study is to investigate the tolerance of adjuvant chemotherapy, measured by functional decline, after surgery for colon cancer stage III in elderly patients. Secondary aims are disease-free survival, toxicity, late functional outcome, quality of life, to establish a geriatric assessment for selection of patients, and to examine the prognostic value of gene signature tests / biomarkers for stage III colon cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Oslo University Hospital
Treatments:
Capecitabine